A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Morphotek
ClinicalTrials.gov Identifier:
NCT00325494
First received: May 11, 2006
Last updated: July 16, 2014
Last verified: July 2014

May 11, 2006
July 16, 2014
May 2006
September 2008   (final data collection date for primary outcome measure)
  • Safety and Tolerability as a measure of Adverse Events/Serious Adverse Events [ Time Frame: 35 day treatment and observation period, or until disease progession occurs ] [ Designated as safety issue: Yes ]
  • Safety and Tolerability as a measure of clinical laboratory parameters [ Time Frame: 35 day treatment and observation period, or until disease progession occurs ] [ Designated as safety issue: No ]
  • Safety and Tolerability as a measure of physical examinations, vital signs, and ECGs [ Time Frame: 35 day treatment and observation period, or until disease progession occurs ] [ Designated as safety issue: No ]
  • Tolerability
  • Safety
Complete list of historical versions of study NCT00325494 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics of MORAb-009 [ Time Frame: Pre-dose, mid-infusion, end of infusion, 30 min, 60 min, 2 hours, and 4 hours post dose ] [ Designated as safety issue: No ]
    Blood samples will be analyzed using ELISA for concentration of MORAb-009.
  • Percentage of Participants With Antibodies Against Infliximab (Human Anti-chimeric Antibody [HACA]) [ Time Frame: 35 day treatment and observation period ] [ Designated as safety issue: No ]
  • Objective Tumor Response Rate Assessed by Investigator [ Time Frame: 35 day treatment and observation period ] [ Designated as safety issue: No ]
    CT; MRI; RECIST criteria; biomarkers
  • Pharmacokinetics
  • Human Anti-Chimeric Antibody formation
  • Objective Tumor Measurement (CT; MRI; RECIST criteria; biomarkers)
Not Provided
Not Provided
 
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-009, a Chimeric Monoclonal Antibody, in Subjects With Advanced Mesothelin-expressing Tumors

The purpose of this study is to establish the safest doses of an investigational drug called MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer. MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface of these cancers.

MORAb-009 is a high-affinity monoclonal antibody raised against human mesothelin, a membrane glycoprotein thought to be involved in cell adhesion and tightly associated with a range of cancers. It has been shown that mesothelin is over-expressed in pancreatic cancers, mesotheliomas, and ovarian or mesothelin-expressing ovarian or non-small cell lung cancers, while showing little expression in normal tissues. Preclinical experiments indicate that MORAb-009 is a potentially useful anti-cancer agent. This clinical trial is being performed to determine the safety of MORAb-009 in subjects with mesothelin-expressing tumors, as well as to establish serum pharmacokinetics of the antibody, and to assess tumor antigens that may serve as predictors of a response to MORAb-009.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Pancreatic Cancer
  • Mesothelioma
  • Ovarian Cancer
  • Non-Small Cell Lung Cancer
Drug: MORAb-009
Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
  • Experimental: Cohort 1
    MORAb-009 weekly dose of 12.5 mg/m^2
    Intervention: Drug: MORAb-009
  • Experimental: Cohort 2
    MORAb-009 weekly dose of 25 mg/m^2
    Intervention: Drug: MORAb-009
  • Experimental: Cohort 3
    MORAb-009 weekly dose of 50 mg/m^2
    Intervention: Drug: MORAb-009
  • Experimental: Cohort 4
    MORAb-009 weekly dose of 100 mg/m^2
    Intervention: Drug: MORAb-009
  • Experimental: Cohort 5
    MORAb-009 weekly dose of 200 mg/m^2
    Intervention: Drug: MORAb-009
  • Experimental: Cohort 6
    MORAb-009 weekly dose of 400 mg/m^2
    Intervention: Drug: MORAb-009
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female or male subjects, ≥ 18 years of age, with a histologically confirmed diagnosis of pancreatic adenocarcinoma, mesothelioma, or mesothelin-positive ovarian or non-small cell lung cancer. As nearly 100% of pancreatic adenocarcinoma and mesotheliomas express mesothelin, immunohistochemical confirmation of mesothelin-positivity is not necessary.
  • Subject must have disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) or evaluable by clinical signs/symptoms (e.g., ascites, pleural effusion, or lesions of less than 2 cm) supported by biomarker, radiologic, or pathologic studies conducted within 4 weeks prior to study entry.
  • Subject must have failed at least one standard chemotherapy regimen. Patients with pancreatic cancer must have received gemcitabine as part of prior therapy and be considered refractory, or in the case of ovarian cancer be considered platinum refractory or resistant.
  • Life expectancy ≥ 3 months, as estimated by the investigator.
  • Eastern Cooperative Oncology Group performance status or 0, 1 or 2.
  • Female subjects of childbearing potential and all male subjects must consent to use a medically acceptable method of contraception throughout the study period and for 28 days after MORAb-009 administration. A barrier method of contraception must be included.
  • Other significant medical conditions must be well controlled and stable in the opinion of the investigator for at least 30 days prior to Study Day 1.
  • Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:

Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; Platelet count ≥ 100 x 109/L; Hemoglobin ≥ 9 g/dL; Serum bilirubin ≤ 2.0 mg/dL; Aspartate transaminase (AST) ≤ 5 x upper limit of normal (ULN); Alanine transaminase (ALT) ≤ 5 x ULN; Alkaline Phosphatase ≤ 5 x ULN; Serum creatinine ≤ 2.0 mg/dL. If the elevations of liver functions are due to obstruction of the common bile duct extrinsic to the liver, the subject may be enrolled at the discretion of the investigator even if the elevations are greater than the limits above. Stenting to reduce liver functions to qualifying levels is permitted.

- Subject must be willing and able to provide written informed consent.

Exclusion Criteria:

  • Known central nervous system (CNS) tumor involvement.
  • Evidence of other active malignancy requiring treatment.
  • Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association Class III or IV, angina not well controlled by medication, or myocardial infarction within 6 months).
  • ECG demonstrating clinically significant arrhythmias (Note: Subjects with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal SVT, are eligible).
  • Active serious systemic disease, including active bacterial or fungal infection.
  • Active hepatitis or HIV infection.
  • Treatment within three months with immunomodulatory therapy (e.g. interferons, immunoglobulin therapy, IL-1RA or systemic corticosteroids). Short term systemic corticosteroids or topical or intra-articular steroids are acceptable, subject to the judgment of the investigator.
  • Chemotherapy, biologic therapy, or immunotherapy within 3 weeks prior to dosing with MORAb-009.
  • Breast-feeding, pregnant, or likely to become pregnant during the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00325494
MORAb-009-001
Not Provided
Morphotek
Morphotek
Not Provided
Study Director: Susan C. Weil, M.D. Morphotek, Inc.
Morphotek
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP